Stocchi, F., Abbruzzese, G., Ceravolo, R., Cortelli, P., D’Amelio, M., De Pandis, M.F., Fabbrini, G., Pacchetti, C., Pezzoli, G., Tessitore, A., Canesi, M., Iannacone, C., Zappia, M. and FORTE Study Group (2014) Prevalence of Fatigue in Parkinson’s Disease and Its Clinical Correlates. Neurology, 83, 215-220.
http://dx.doi.org/10.1212/WNL.0000000000000587

has been cited by the following article:

• TITLE: Safety and Efficacy of a Transdermal Rotigotine for the Treatment of Fatigue and Quality of Life in Patients with Parkinson’s Disease

  AUTHORS: Kazuo Abe, Masashi Fujita, Hiroo Yoshikawa

  KEYWORDS: Parkinson’s Disease, Non-Motor Symptoms, Fatigue, Quality of Life, Transdermal Rotigotine

  JOURNAL NAME: Advances in Parkinson's Disease, Vol.4 No.4, November 13, 2015

  ABSTRACT: Aim: To evaluate safety and efficacy of a transdermal rotigotine for the treatment of fatigue and quality of life (QOL) in patients with Parkinson’s disease (PD). This was a multi-sites open-label study of 58 PD patients (male 26, female 32) who met a Japanese PD diagnosis criterion. They received a transdermal rotigotine 4.5 mg/day for 8 weeks. We added a rotigotine on the previous anti-Parkinson’s drugs. Clinical signs were evaluated by Hoehn-Yahr (H-Y) stage, unified Parkinson’s disease rating scale (UPDRS), fatigue severity scale (FSS), and Euro quality of life (QOL). The scores of UPDRS improved from 35.2 ± 8.0 (mean ± SD) to 31.8 ± 8.3 (P = 0.14). There was no significant improvement or worsening of the H-Y stages. The scores of FSS improved from 57.3 ± 12.7 (mean ± SD) to 50.1 ± 11.8 (P = 0.061). The scores of QOL improved from 38.1 ± 11.1 to 48.3 ± 10.0 (P = 0.068). Our data demonstrate that, in a small sample size, administration of a transdermal rotigotine was associated with few side effects and was modestly effective for the treatment of fatigue and QOL in patients with PD.